Meeder Asset Management Inc Fibrogen Inc Transaction History

Meeder Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$32.57 - $42.83 $260 - $342	-8 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$23.3 - $45.96 $11,370 - $22,428	-488 Reduced 98.39%	8 $0
Q4 2019 Feb 13, 2020	SELL	$34.58 - $48.06 $1,175 - $1,634	-34 Reduced 6.42%	496 $21,000
Q3 2019 Oct 17, 2019	BUY	$36.98 - $48.45 $19,599 - $25,678	530 New	530 $20,000
Q2 2019 Aug 05, 2019	SELL	$35.13 - $55.53 $171,891 - $271,708	-4,893 Closed	0 $0
Q1 2019 Apr 16, 2019	BUY	$42.83 - $59.91 $183,269 - $256,354	4,279 Added 696.91%	4,893 $264,000
Q4 2018 Jan 17, 2019	BUY	$37.97 - $60.16 $20,086 - $31,824	529 Added 622.35%	614 $28,000
Q3 2018 Nov 02, 2018	SELL	$56.3 - $67.25 $3,490 - $4,169	-62 Reduced 42.18%	85 $0
Q2 2018 Jul 24, 2018	BUY	$44.9 - $64.95 $2,783 - $4,026	62 Added 72.94%	147 $0
Q1 2018 May 03, 2018	SELL	$45.35 - $61.65 $59,000 - $80,206	-1,301 Reduced 93.87%	85 $4,000
Q4 2017 Feb 02, 2018	BUY	$41.95 - $60.1 $32,511 - $46,577	775 Added 126.84%	1,386 $65,000
Q3 2017 Oct 20, 2017	BUY	$33.4 - $53.9 $20,407 - $32,932	611	611 $33,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.